1. Show article details.

    U.S. appeals court ruling may clear barrier to generic OxyContin

    Reuters – 8:12 PM ET 02/01/2016

    A federal appeals court ruled Monday that four patents related to Purdue Pharma's painkiller OxyContin are invalid, potentially bringing Teva Pharmaceutical Industries Ltd (TEVA) and others a step closer to introducing generic versions of the drug.

  2. Show article details.

    U.S. appeals court ruling may clear barrier to generic OxyContin

    Reuters – 3:38 PM ET 02/01/2016

    A federal appeals court ruled Monday that four patents related to Purdue Pharma's painkiller OxyContin are invalid, potentially bringing Teva Pharmaceutical Industries Ltd (TEVA) and others a step closer to introducing generic versions of the drug.

  3. Show article details.

    Mylan to Report Fourth Quarter and Full Year 2015 Financial Results on Feb. 10, 2016

    PR Newswire – 2:57 PM ET 01/21/2016

    HERTFORDSHIRE, England and PITTSBURGH, Jan. 21, 2016 Mylan N.V. (MYL) today announced that it will host a conference call and live webcast, including a slide presentation, on Wednesday, Feb. 10, 2016, at 4:30 p.m. ET, to review the company's financial results for the fourth quarter and year ended Dec. 31, 2015. The company also will provide its financial guidance for 2016.

  4. Show article details.

    After Greenlight's 2015 dive, Einhorn bets on Macy's -letter

    Reuters – 12:43 PM ET 01/19/2016

    David Einhorn, whose Greenlight Capital hedge fund ranked among last year's worst performers, told investors on Tuesday that he has made new bets on stocks including battered retailer Macy's (M) and is currently concentrating on delivering better returns. Einhorn's fund, which had only one other losing year since opening for business in 1996, tumbled 20.2 percent in 2015.

  5. Show article details.

    Einhorn, after terrible 2015, takes new stake in Macy's -letter

    Reuters – 11:24 AM ET 01/19/2016

    David Einhorn, whose Greenlight Capital hedge fund ranked among last year's worst performers, told investors on Tuesday that he has made new bets on stocks including battered retailer Macy's (M) and is currently concentrating on delivering better returns.

  6. Show article details.

    Mylan Launches Generic Felbatol® Tablets

    PR Newswire – 10:26 AM ET 01/19/2016

    HERTFORDSHIRE, England and PITTSBURGH, Jan. 19, 2016 Mylan N.V. (MYL) today announced the U.S. launch of Felbamate Tablets USP, 400 mg and 600 mg, which is the generic version of Meda Pharms' Felbatol® Tablets. Felbamate Tablets USP, 400 mg and 600 mg, had U.S. sales of approximately $53 million for the 12 months ending Nov. 30, 2015, according to IMS Health.

  7. Show article details.

    U.S. copy of GSK's Advair a step closer as Mylan files generic version

    Reuters – 3:43 AM ET 01/12/2016

    The arrival of cheap generic versions of GlaxoSmithKline's top-selling lung drug Advair has moved a step closer with confirmation from Mylan that it has submitted a generic version for approval. Mylan said late on Monday it had filed an abbreviated new drug application to the U.S. Food and Drug Administration in December.

  8. Show article details.

    Mylan Confirms FDA Submission of ANDA for Generic Advair Diskus®

    PR Newswire – 5:11 PM ET 01/11/2016

    HERTFORDSHIRE, England and PITTSBURGH, Jan. 11, 2016 In advance of its upcoming presentation at the J.P. Morgan Annual Healthcare Conference tomorrow, Mylan N.V. (MYL) today confirmed that it submitted its abbreviated new drug application for fluticasone propionate 100, 250, 500 mcg and salmeterol 50 mcg inhalation powder to the U.S. Food and Drug Administration in Dec. 2015.

  9. Show article details.

    Momenta, Mylan to jointly develop six biosimilars

    MarketWatch – 9:37 AM ET 01/08/2016

    Companies will equally share R&D costs and profits. Mylan NV (MYL) and Momenta Pharmaceuticals Inc. (MNTA) said Friday they would jointly develop and commercialize six biosimilars. Mylan will make an upfront cash payment of $45 million to Momenta and could pay up to $200 million if milestones are reached.

  10. Show article details.

    Momenta, Mylan to Jointly Develop Six Biosimilars

    DJ Business News – 9:35 AM ET 01/08/2016

    Mylan NV (MYL) and Momenta Pharmaceuticals Inc. (MNTA) said Friday they would jointly develop and commercialize six biosimilars. Mylan will make an upfront cash payment of $45 million to Momenta and could pay up to $200 million if milestones are reached. Each company will equally share the development costs and eventual profits.

  11. Show article details.

    Mylan CFO John Sheehan to Retire as of April 1, 2016

    PR Newswire – 9:00 AM ET 01/08/2016

    HERTFORDSHIRE, England and PITTSBURGH, Jan. 8, 2016  Mylan N.V. (MYL) today announced that John Sheehan has advised the company of his intention to retire from his position as CFO of Mylan, effective April 1, 2016. Mylan's Board of Directors has initiated a search to identify a replacement for Mr. Sheehan.

  12. Show article details.

    Mylan Announces Worldwide Collaboration with Momenta to Jointly Develop and Commercialize Six Biosimilar Products

    PR Newswire – 8:00 AM ET 01/08/2016

    HERTFORDSHIRE, England and PITTSBURGH, Jan. 8, 2016 Mylan N.V. (MYL) today announced that it has entered into an exclusive global collaboration agreement with Momenta Pharmaceuticals, Inc. (MNTA) to develop, manufacture and commercialize six of Momenta's current biosimilar candidates, including Momenta's biosimilar candidate, ORENCIA®. Mylan CEO Heather Bresch commented, "Mylan's long-stated strategy has be...

  13. Show article details.

    Momenta Pharmaceuticals Announces Worldwide Collaboration With Mylan to Jointly Develop and Commercialize Six Biosimilar Products

    GlobeNewswire – 8:00 AM ET 01/08/2016

    Momenta Pharmaceuticals, Inc. today announced that it has entered into an exclusive global collaboration agreement with Mylan N.V. (MYL), to develop, manufacture and commercialize six of Momenta’s current biosimilar candidates, including Momenta’s biosimilar candidate ORENCIA®. “We are thrilled to welcome Mylan as our new collaboration partner for biosimilars.

  14. Show article details.

    Mylan Launches Generic Harvoni® (Ledipasvir/Sofosbuvir) Under the Brand Name MyHep LVIR™ in India

    PR Newswire – 8:00 AM ET 01/07/2016

    HERTFORDSHIRE, England and BANGALORE, India and PITTSBURGH, Jan. 7, 2016 Mylan N.V. (MYL) today announced that its subsidiary, Mylan Pharmaceuticals Private Limited, has launched generic Harvoni® tablets under the brand name MyHep LVIR™ in India.

  15. Show article details.

    Phosphagenics initiates arbitration against Mylan

    Reuters – 7:17 AM ET 01/06/2016

    Phosphagenics Ltd (POSGF) : * Phosphagenics (POSGF) initiates arbitration against mylan * Says substantive hearing is expected to take place in late 2016 * Claims for alleged breaches of agreements related to development and commercialisation of Phosphagenics (POSGF)' tpm formulation of injectable antibiotic daptomycin * Says the licensing agreement continues in full force and effect pending the arbitrator's decision...

  16. Show article details.

    Mylan Launches Generic Ortho Tri-Cyclen Lo® Tablets

    PR Newswire – 10:34 AM ET 01/05/2016

    HERTFORDSHIRE, England and PITTSBURGH, Jan. 5, 2016 Mylan N.V. (MYL) today announced the U.S. launch of Norgestimate and Ethinyl Estradiol Tablets USP, 0.18 mg/0.025 mg, 0.215 mg/0.025 mg, and 0.25 mg/0.025 mg, which is the generic version of Janssen's Ortho Tri-Cyclen Lo® Tablets.

  17. Show article details.

    Bests And Bloopers From M&A's Epic Year

    DJ Business News – 2:47 AM ET 01/02/2016

    A high-stakes affair in normal times, corporate deal making took on even greater weight in 2015, the busiest year ever for mergers. At the end of the roughly $5 trillion year, The Wall Street Journal's deals team presents its view on who gained the most from the bonanza, and who lost out-- or as we call them in our annual offering, the bests and the bloopers. The year's biggest deal maker was arguably one of the most successful, too.

  18. Show article details.

    Friday trading needed for Israel to join MSCI Europe index

    Reuters – 7:46 AM ET 12/29/2015

    Trading on Fridays is a necessary requirement to have Israel included in the MSCI Europe index, the chief executive of the Tel Aviv Stock Exchange said on Tuesday. Currently the TASE conducts trading from Sundays to Thursdays, in line with Israel's work week, but is contemplating moving to a Monday to Friday schedule.

  19. Show article details.

    Mylan Launches Generic Zyvox® Tablets

    PR Newswire – 7:00 AM ET 12/29/2015

    HERTFORDSHIRE, England and PITTSBURGH, Dec. 29, 2015  Mylan N.V. (MYL) today announced the U.S. launch of Linezolid Tablets, 600 mg, which is the generic version of Pfizer's Zyvox® Tablets. Linezolid Tablets, 600 mg, had U.S. sales of approximately $457.8 million for the 12 months ending Sept. 30, 2015, according to IMS Health.

  20. Show article details.

    Trading on Fridays needed to move Israel to MSCI Europe index

    Reuters – 4:36 AM ET 12/29/2015

    Trading on Fridays is a necessary requirement to have Israel included in the MSCI Europe index, the chief executive of the Tel Aviv Stock Exchange said on Tuesday. Currently TASE conducts trading from Sundays to Thursdays but is studying a move to a Monday to Friday week.

Page:

Today's and Upcoming Events

  • Feb
    10

    MYL to announce Q4 earnings After Market (Confirmed)

  • Feb
    10

    MYL Earnings Conference Call at 4:30 PM Listen

Past Events (last 90 days)

  • Jan
    7

    Shareholders Meeting

Data provided by Wall Street Horizon, Inc. © 2016

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.